Dexmedetomidine Altan Pharma 4 mikrogram/ml Infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dexmedetomidine altan pharma 4 mikrogram/ml infusionsvätska, lösning

altan pharma limited - dexmedetomidinhydroklorid - infusionsvätska, lösning - 4 mikrogram/ml - dexmedetomidinhydroklorid 4,727 mikrog aktiv substans; glukosmonohydrat hjälpämne

Carbamazepine Essential Pharma 125 mg Suppositorium Sverige - svenska - Läkemedelsverket (Medical Products Agency)

carbamazepine essential pharma 125 mg suppositorium

essential pharma (m) ltd - karbamazepin - suppositorium - 125 mg - karbamazepin 125 mg aktiv substans - karbamazepin

Carbamazepine Essential Pharma 250 mg Suppositorium Sverige - svenska - Läkemedelsverket (Medical Products Agency)

carbamazepine essential pharma 250 mg suppositorium

essential pharma (m) ltd - karbamazepin - suppositorium - 250 mg - karbamazepin 250 mg aktiv substans - karbamazepin

Tetracyklin RPH Pharma 250 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

tetracyklin rph pharma 250 mg tablett

rph pharmaceuticals ab - tetracyklinhydroklorid - tablett - 250 mg - sackaros hjälpämne; tetracyklinhydroklorid 250 mg aktiv substans; laktosmonohydrat hjälpämne - tetracyklin

Fingolimod Unimedic Pharma 0,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fingolimod unimedic pharma 0,5 mg kapsel, hård

unimedic pharma ab - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans

Ribavirin Teva Pharma B.V. Europeiska unionen - svenska - EMA (European Medicines Agency)

ribavirin teva pharma b.v.

teva b.v. - ribavirin - hepatit c, kronisk - antivirala medel för systemisk användning - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4 och 5. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 och 5.

Mycophenolate mofetil Cross Pharma 500 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mycophenolate mofetil cross pharma 500 mg filmdragerad tablett

cross pharma ab - mykofenolatmofetil - filmdragerad tablett - 500 mg - mykofenolatmofetil 500 mg aktiv substans

Dasatinib Accordpharma Europeiska unionen - svenska - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Buprenorphine/Naloxone G.L. Pharma 8 mg/2 mg Resoriblett, sublingual Sverige - svenska - Läkemedelsverket (Medical Products Agency)

buprenorphine/naloxone g.l. pharma 8 mg/2 mg resoriblett, sublingual

g.l. pharma gmbh - buprenorfinhydroklorid; naloxonhydrokloriddihydrat - resoriblett, sublingual - 8 mg/2 mg - naloxonhydrokloriddihydrat 2,44 mg aktiv substans; buprenorfinhydroklorid 8,64 mg aktiv substans; laktosmonohydrat hjälpämne; mannitol hjälpämne

Buprenorphine/Naloxone G.L. Pharma 4 mg/1 mg Resoriblett, sublingual Sverige - svenska - Läkemedelsverket (Medical Products Agency)

buprenorphine/naloxone g.l. pharma 4 mg/1 mg resoriblett, sublingual

g.l. pharma gmbh - buprenorfinhydroklorid; naloxonhydrokloriddihydrat - resoriblett, sublingual - 4 mg/1 mg - mannitol hjälpämne; laktosmonohydrat hjälpämne; naloxonhydrokloriddihydrat 1,22 mg aktiv substans; buprenorfinhydroklorid 4,32 mg aktiv substans